Loading company
Intelligent BIO Solutions Inc.
INBS · Nasdaq · ·
Next earnings: November 11, 2026
$1.650.0%Sep 29 close
- 1M
- -30.1%
- 6M
- -42.5%
- 1Y
- -83.8%
- 5Y
- -100.0%
INBS · Nasdaq · ·
Next earnings: November 11, 2026
$1.650.0%Sep 29 close
Intelligent BIO Solutions Inc. is scheduled to report next on November 11, 2026. The date comes from Nasdaq’s earnings calendar, and companies sometimes move it.
The quarter ending June 30, 2026, against the same quarter a year earlier.
| Measure | 3 months toJun 30, 2026 | 3 months toJun 30, 2025 | Change |
|---|---|---|---|
| Total Revenue | $1.1M | $843.9K | +35.78% |
| Profit | -$3.9M | -$3.1M | -26.46% |
| Profit per share | -$0.90 | -$0.70 | -28.57% |
These are single quarters, not a trailing year — the figures elsewhere on this site cover twelve months and will be much larger. A seasonal business swings a long way between the two: ServiceNow earns $2.0B of free cash flow in its December quarter and $0.5B in its June one.
Compared against the same quarter a year earlier, not against an analyst forecast. A “beat” or “miss” needs a consensus estimate, which is licensed data we do not carry — and getting it wrong is worse than leaving it out.
Intelligent BIO Solutions Inc. has no earnings call transcript available.
“Fiscal 2026 was a year of clear, compounding progress across every aspect of our business,”
Quoted verbatim from the release, and shown only when the filing attributes it to a named person.
Releases land after the close or before the open, so the move is the session that follows.
Intelligent Bio Solutions Inc. (Nasdaq: INBS) is a medical technology company delivering intelligent, rapid, non-invasive testing solutions. The Company believes that its Intelligent Fingerprinting Drug Screening System will revolutionize portable testing through fingerprint sweat analysis, which has the potential for broader applications in additional fields. Designed as a hygienic and cost-effective system, the test screens for the recent use of drugs commonly found in the workplace, including opiates, cocaine, methamphetamine, and cannabis. With sample collection in seconds and results in under ten minutes, this technology would be a valuable tool for employers in safety-critical industries. The Company’s current customer segments outside the U.S. include construction, manufacturing and engineering, transport and logistics firms, mining, drug treatment organizations, and coroners.
The company’s own description, as it appears at the foot of the release.
The quote and the company description come from Intelligent BIO Solutions Inc.’s Item 2.02 8-K filed August 19, 2026; the table is built from its quarterly reports. Read the release on EDGAR Share prices are split- and dividend-adjusted.